Butterfly Medical is an innovative brand that specializes in developing implantable devices for the treatment of Benign Prostatic Hyperplasia (BPH). With a focus on providing superior alternatives to existing BPH minimally invasive treatments, Butterfly Medical aims to improve the quality of life for men suffering from this condition. Their investigational device offers a non-surgical, permanent solution that can be performed in an office-based setting under local anesthesia, with the procedure taking just 10 minutes.

Clinical trials have shown excellent results, including good dilation of the prostate urethra and improved voiding for patients, with no side effects. BPH, which affects 50% of men above 60 and over 70% of men above 70, can have a significant impact on quality of life. Approximately 30 million men worldwide experience BPH symptoms, and Butterfly Medical's device offers a much-needed treatment option.

The company is led by a team of experienced professionals with a deep understanding of the urology market and extensive expertise in developing innovative medical technologies. Butterfly Medical has received FDA approval to start its US pivotal trial and has also received the prestigious CE mark for its next-generation medical device. They have been recognized for their achievements, including being named the Diamond Winner in the 2019 MassChallenge Israel cohort.

Butterfly Medical's ongoing clinical trial in Israel has successfully treated 50 patients and is currently enrolling participants in multiple medical centers. To learn more about their groundbreaking treatment or participate in the trial, you can contact Butterfly Medical at info@butterfly-medical. com